Human chronic myeloid leukemia (CML) cell lines selected for multidrug resistance (MDR), such as Lucena (a vincristine-selected derivative of K562), coordinately overexpress the ABC efflux transporters ABCB1, ABCG2 and ABCC1 together with the pluripotency/stem-cell transcription factor Oct-4, and the promoters of all three transporter genes carry canonical Oct-4 binding motifs. Whether Oct-4 directly and causally regulates these transporters — and hence whether a 'stemness-to-MDR' program exists in CML — has never been established at the level of transcriptional mechanism. The open problem is to establish or refute direct Oct-4 control of ABCB1/ABCG2/ABCC1 transcription in these cells.

Background

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion tyrosine kinase. The K562 cell line, derived from a CML patient in blast crisis, is a standard in-vitro CML model. Stepwise exposure of K562 to cytotoxic drugs yields MDR derivatives: the Lucena line (selected with vincristine) and the FEPS line, both of which strongly overexpress the ATP-binding-cassette (ABC) efflux transporter ABCB1 (P-glycoprotein), with FEPS also overexpressing ABCC1 (MRP1). ABC transporters pump chemotherapeutic drugs out of cells and are a principal mechanism of multidrug resistance (MDR). ABCG2 (BCRP) is a related ABC efflux transporter. Oct-4, encoded by the gene POU5F1, is a POU-family transcription factor essential for pluripotency in embryonic stem cells; it binds an 8-bp octamer motif (ATGCAAAT) and is frequently used as a tumor/stem-cell marker, often together with the cooperating pluripotency transcription factors Sox2 and NANOG. CD34 and CD38 are surface markers used to immunophenotype hematopoietic cells: CD34+CD38− is the profile of early hematopoietic (and leukemic) stem/progenitor cells. Marques et al. (2010) reported that "the results suggest that both cell lines possess CD34+CD38- profiles", that the promoter regions of ABCB1, ABCG2 and ABCC1 contain binding sites for the Oct-4 transcription factor, and that Lucena cells show an over-expression of ABCB1 and high expression of Oct-4, ABCG2 and ABCC1 compared with K562. The review by Rumjanek et al. (2013) tabulates the corresponding RT-qPCR mRNA values for Lucena-1 versus K562, citing that paper, as Oct-4 ≈3-fold, ABCG2 ≈4-fold and ABCC1 ≈1.5-fold, with ABCB1 mRNA listed as "High" and no fold value; the same table records an "Equal" ABCG2 mRNA RT-qPCR result from a different study of the same cell-line pair. Because motif presence plus co-expression is only circumstantial evidence, the causal and mechanistic questions remain open: the review of the MDR-CML cell-line model (Rumjanek et al., 2013) treated Oct-4-driven transporter expression as explicitly hypothetical ('reasonable to assume' a role similar to that in cancer stem cells), reported the motif data only as the presence of an Oct-4 core sequence (ATGCAAAT) in the promoters of ABCB1, ABCC1 and ABCG2, and noted controversy about K562 CD34 expression. A practical complication, now well recognized, is that OCT4 detection in cancer cell lines is confounded by alternative isoforms (OCT4B) and by pseudogenes such as OCT4-PG1, which the same Brazilian group later showed can itself modulate OCT-4 protein levels and the MDR phenotype in FEPS cells — making isoform/pseudogene-resolved reagents an important practical consideration for any causal test.

Several related open questions in this system, on which the target question does not depend, remain unresolved: the molecular basis of the unequal induction among the three transporters in the MDR lines (ABCB1 strongly overexpressed, with Oct-4, ABCG2 and ABCC1 only modestly elevated) even though Oct-4 binding sites are reported in all three promoters; whether the Oct-4/ABC-transporter co-expression program is present in primary CML cells or is an artifact of in-vitro drug selection; and why parental K562 cells remain non-MDR although both lines have been reported to share a CD34+CD38− stem-like surface profile, a phenotype that Marques et al. (2010) state in hedged form and that Rumjanek et al. (2013) record as controversial for K562 CD34 expression. The translational endpoint of the axis — which transporter or regulatory interaction must be targeted to reverse MDR without compromising normal stem-cell functions — is the applied consequence of the target question rather than a separate objective.

Problem Statement

Establish or refute, at the level of direct transcriptional mechanism, the proposed stemness-to-multidrug-resistance axis in chronic myeloid leukemia cells in which Oct-4/POU5F1 drives ABC-transporter expression. Concretely: determine whether Oct-4 directly occupies and activates the ABCB1, ABCG2 and ABCC1 promoters in the K562/Lucena cell-line pair (extension to related K562-derived MDR lines such as FEPS is optional rather than required) — that is, whether the Oct-4 binding sites reported in these three promoters, together with the elevated Oct-4 and elevated ABCB1, ABCG2 and ABCC1 expression in Lucena relative to K562, reflect a direct Oct-4-driven transcriptional program. All three promoters are the target set: a determination that covers only one or two of them is a partial result and does not resolve the question. Evidence bearing on direct transcriptional mechanism is what resolves the question. A rigorous refutation resolves the question equally.

Related open questions of the same system, described in Background, and the translational endpoint of the axis are context rather than required deliverables of the target question.

References

  1. Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leukemia Research 2010;34(6):757-762. doi:10.1016/j.leukres.2009.11.004 (PMID 19969351). https://doi.org/10.1016/j.leukres.2009.11.004
  2. Tiwari AK, An X, Chen ZS. The role of stem cell markers in multidrug resistance mediated by ABC transporters. Leukemia Research 2010;34(6):696-697. doi:10.1016/j.leukres.2009.12.007 (PMID 20061021). https://doi.org/10.1016/j.leukres.2009.12.007
  3. Rumjanek VM, Vidal RS, Maia RC. Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? Bioscience Reports 2013;33(6):e00081. doi:10.1042/BSR20130067 (PMID 24070327; PMC3839595). https://doi.org/10.1042/BSR20130067
  4. Oliveira BR, Figueiredo MA, Trindade GS, Marins LF. OCT4 mutations in human erythroleukemic cells: implications for multiple drug resistance (MDR) phenotype. Molecular and Cellular Biochemistry 2015;400(1-2):41-50. doi:10.1007/s11010-014-2260-7 (PMID 25355160). https://doi.org/10.1007/s11010-014-2260-7
  5. Moreira MA, Bagni C, de Pinho MB, Mac-Cormick TM, dos Santos Mota M, Pinto-Silva FE, Daflon-Yunes N, Rumjanek VM. Changes in gene expression profile in two multidrug resistant cell lines derived from a same drug sensitive cell line. Leukemia Research 2014;38(8):983-987. doi:10.1016/j.leukres.2014.06.001 (PMID 24996974). https://doi.org/10.1016/j.leukres.2014.06.001
  6. Carrett-Dias M, Almeida LK, Pereira JL, Almeida DV, Filgueira DM, Marins LF, Votto AP, Trindade GS. Cell differentiation and the multiple drug resistance phenotype in human erythroleukemic cells. Leukemia Research 2016;42:13-20. doi:10.1016/j.leukres.2016.01.008 (PMID 26852002). https://doi.org/10.1016/j.leukres.2016.01.008
  7. Lettnin AP, Wagner EF, Carrett-Dias M, Dos Santos Machado K, Werhli A, Cañedo AD, Trindade GS, de Souza Votto AP. Silencing the OCT4-PG1 pseudogene reduces OCT-4 protein levels and changes characteristics of the multidrug resistance phenotype in chronic myeloid leukemia. Molecular Biology Reports 2019;46(2):1873-1884. doi:10.1007/s11033-019-04639-4 (PMID 30721421). https://doi.org/10.1007/s11033-019-04639-4
  8. Lettnin AP, Wagner EF, Salgado MTSF, Cañedo AD, Rumjanek VM, Trindade GS, Votto APS. Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia. Gene 2024;892:147848. doi:10.1016/j.gene.2023.147848 (PMID 37774806). https://doi.org/10.1016/j.gene.2023.147848
  9. Hosokawa Y, Takahashi H, Inoue A, Kawabe Y, Funahashi Y, Kameda K, Sugimoto K, Yano H, Harada H, Kohno S, Ohue S, Ohnishi T, Tanaka J. Oct-3/4 modulates the drug-resistant phenotype of glioblastoma cells through expression of ATP binding cassette transporter G2. Biochimica et Biophysica Acta 2015;1850(6):1197-1205. doi:10.1016/j.bbagen.2015.01.017 (PMID 25644290). https://doi.org/10.1016/j.bbagen.2015.01.017
  10. Xin H, Kong Y, Jiang X, Wang K, Qin X, Miao ZH, Zhu Y, Tan W. Multi-drug-resistant cells enriched from chronic myeloid leukemia cells by Doxorubicin possess tumor-initiating-cell properties. Journal of Pharmacological Sciences 2013;122(4):299-304. doi:10.1254/jphs.13025fp (PMID 23903006). https://doi.org/10.1254/jphs.13025fp
  11. Cui XY, Skretting G, Jing Y, Sun H, Sandset PM, Sun L. Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells. Blood Cells, Molecules & Diseases 2013;51(3):177-184. doi:10.1016/j.bcmd.2013.05.003 (PMID 23725749). https://doi.org/10.1016/j.bcmd.2013.05.003
  12. Hu K, Zhang J, Zhang Y, Wu X, Jin X, Mao S, Ding P, Wu S, Ren J. Lupiwighteone as an Antitumor Agent Reverses Multidrug Resistance in K562/ADR Cells by Regulating Cellular Prion Protein-Oct4 Axis. Anti-Cancer Agents in Medicinal Chemistry 2024;24(20):1514-1524. doi:10.2174/0118715206316284240807100226 (PMID 39129165). https://doi.org/10.2174/0118715206316284240807100226
  13. Trojani A, Pungolino E, Dal Molin A, Lodola M, Rossi G, D'Adda M, Perego A, Elena C, Turrini M, Borin L, Bucelli C, Malato S, Carraro MC, Spina F, Latargia ML, Artale S, Spedini P, Anghilieri M, Di Camillo B, Baruzzo G, De Canal G, Iurlo A, Morra E, Cairoli R. Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment. PLoS ONE 2019;14(7):e0218444. doi:10.1371/journal.pone.0218444 (PMID 31318870). https://doi.org/10.1371/journal.pone.0218444